ライフサイエンスコーパス: surgical therapy

1 fit at mid-term over medical or conventional surgical therapy.

2 rk as an adjunct to periodontal regenerative surgical therapy.

3 selecting the most appropriate patients for surgical therapy.

4 ned to assess the effect of decision aids on surgical therapy.

5 reactive, and to discover the effect of non-surgical therapy.

6 favorable outcome with combined medical and surgical therapy.

7 ovements in medical therapy, and advances in surgical therapy.

8 adjuvant chemotherapy is critical in guiding surgical therapy.

9 conservative treatment are likely to require surgical therapy.

10 l advantage in early-stage lung cancer after surgical therapy.

11 cancer in 1992 to 1999 who underwent primary surgical therapy.

12 should be evaluated for possible multimodal surgical therapy.

13 redictive model would help direct subsequent surgical therapy.

14 s been found to be predictive of response to surgical therapy.

15 lications and death is important in planning surgical therapy.

16 in mean PD and PAL-V were obtained following surgical therapy.

17 , increased use of chemotherapy, and salvage surgical therapy.

18 etastases in 5 patients, excluding them from surgical therapy.

19 omy, being considered a technical failure of surgical therapy.

20 ses constitutional symptoms should undergo a surgical therapy.

21 when severe, lead to complications requiring surgical therapy.

22 ase, relating pathophysiology to medical and surgical therapy.

23 of the fetal lung that are amenable to fetal surgical therapy.

24 astatic disease is crucial to the success of surgical therapy.

25 rapeutic options available to them for their surgical therapy.

26 ic Heller myotomy is emerging as the optimal surgical therapy.

27 have helped to establish the indications for surgical therapy.

28 prevent stroke with appropriate medical and surgical therapy.

29 following SRP, and 6 and 12 months following surgical therapy.

30 mogeneous OL need close monitoring after any surgical therapy.

31 red to baseline at 6 and 12 months following surgical therapy.

32 r complications warranting interventional or surgical therapy.

33 e in relieving DH in patients undergoing non-surgical therapy.

34 aining probiotic sachet as an adjunct to non-surgical therapy.

35 s of patients and to reduce the morbidity of surgical therapy.

36 d there was significantly less CAL gain with surgical therapy.

37 rse and remained unresponsive to medical and surgical therapy.

38 eatic cancer to facilitate possible curative surgical therapy.

39 ty and 4 patients with cardiac sarcoma after surgical therapy.

40 linical scenarios compared with conventional surgical therapy.

41 utilization may allow for greater access to surgical therapy.

42 ts with BCNS and may offer an alternative to surgical therapy.

43 he shifting consensus toward more aggressive surgical therapy.

44 f survival and should be the primary goal of surgical therapy.

45 ital factors were associated with receipt of surgical therapy.

46 ted comorbidities, 273 (51%) did not receive surgical therapy.

47 20 patients (47%) with early HCC received no surgical therapy.

48 weeks following SRP, and 6 months following surgical therapy.

49 c confirmation of HCC, 246 (33%) received no surgical therapy.

50 f patients with early HCC through the use of surgical therapy.

51 and relies on knowledge of both medical and surgical therapies.

52 e pathogenesis, medical therapies as well as surgical therapies.

53 terms of their responsiveness to medical or surgical therapies.

54 evidence-based medicine to the evaluation of surgical therapies.

55 h the appropriate combination of medical and surgical therapies.

56 r selecting patients following CMT for local surgical therapies.

57 enefit from aggressive adjunctive medical or surgical therapies.

58 ents who are reasonable candidates for these surgical therapies.

59 pical steroid treatments or other medical or surgical therapies.

60 of the long-term adverse consequences of our surgical therapies.

61 c investigations, and innovative medical and surgical therapies.

62 candidates for various catheter-directed or surgical therapies.

63 ents and obviate the need for reconstructive surgical therapies.

64 were collected initially, 4 weeks after non-surgical therapy, 10 weeks after surgical therapy, and y

65 he 1984 patients, 1468 had BCS as an initial surgical therapy (75.4%) and 460 had initial mastectomy,

66 Despite improvements in medical and surgical therapies, a significant portion of patients wi

67 d a deviation from guidelines for definitive surgical therapy, adjuvant chemotherapy, and adjuvant ho

68 ovascular clinician on the current status of surgical therapies aimed at achieving reverse ventricula

69 Knowledge of both medical and surgical therapies aimed at improving ventricular effici

70 rgical periodontal therapy (test) versus non-surgical therapy alone (control) was evaluated.

71 The recognition that surgical therapy alone leads to a local failure rate of

72 (P < .001): (1) among the cases treated with surgical therapy alone, 24-month OS rates were 95.9% (95

73 Subsequent to surgical therapy, alterations in bone levels at the alve

74 ng chemotherapy responded to periodontal non-surgical therapy, although with less favorable results t

75 s on the choice for surgery and knowledge of surgical therapy among women with early-stage breast can

76 lowed us to recognize the utility of certain surgical therapies and the need to further study others.

77 dence to support the use of endovascular and surgical therapy and in some areas, for updated guidelin

78 severity of HF was strongly associated with surgical therapy and subsequent mortality, whereas valvu

79 f which patients will fail sphincter-sparing surgical therapy and ultimately require fecal diversion.

80 n), at 60 days (30 days after the end of non-surgical therapy), and at 150 days (90 days after surger

81 ting diseases that are not amenable to other surgical therapies, and are reasonably anticipated to be

82 ase risk, diagnosis, response to medical and surgical therapies, and prognosis for recurrence.

83 screening for VUR, the benefits and risks of surgical therapy, and economic factors.

84 Eleven patients had primary surgical therapy, and five required subsequent surgery.

85 All patients received combined medical and surgical therapy, and none died, but they had serious co

86 s tumor characteristics, diagnostic studies, surgical therapy, and surveillance methods were reviewed

87 patients with infective endocarditis, use of surgical therapy, and their associations with patient ou

88 diagnosis of cholangiocarcinoma, medical and surgical therapy, and timing and outcome of liver transp

89 s after non-surgical therapy, 10 weeks after surgical therapy, and yearly during SPT.

90 tested patients; 2) the effectiveness of non-surgical therapy; and 3) the relative risk of disease pr

91 tudies comparing antibiotic therapy (AT) and surgical therapy-appendectomy (ST) for uncomplicated app

92 Dopaminergic and surgical therapies are associated with potentially serio

93 Surgical therapies are available for the treatment of IC

94 Surgical therapies are effective in reducing essential t

95 Novel pharmacological, immunologic, and surgical therapies are leading to improved quality of li

96 Many of these surgical therapies are still in the experimental or clin

97 A variety of promising new medical and surgical therapies are under investigation, but further

98 furcation defects compared with conventional surgical therapy are presented.

99 Medical, laser, and surgical therapy are similar to treatment of primary ope

100 iminished response to symptomatic medical or surgical therapy as the disease progresses(2).

101 oved at the end of the third month after non-surgical therapy associated with antibiotics.

102 As endovascular surgical therapies became widespread, GSR vascular case

103 specific therapy for BA; however, sequential surgical therapy begins with creation of a hepatoportoen

104 o identify incident cancer cases and initial surgical therapy both singly and in combination.

105 Medical and surgical therapy both still result in a large number of

106 ation of nutritional, medical, hormonal, and surgical therapies can be effective in preventing liver

107 Surgical therapy can be accomplished at experienced cent

108 Surgical therapy can be mutilating and often has signifi

109 Surgical therapy can be quite beneficial for patients wh

110 motor network have suggested that medical or surgical therapy can promote a prokinetic state by induc

111 probing depths beyond that attained with non-surgical therapy, clinicians need to consider the advant

112 The Surgical Therapies Commission of the International Leagu

113 -8 levels decreased until 3 months after non-surgical therapy compared with baseline in T and G allel

114 Each patient received surgical therapy consisting of regenerative therapy usin

115 The results of surgical therapy consisting of the clinical parameters o

116 g the clinical management of these tumors as surgical therapies continue to improve.

117 alysis of data from the Clinical Outcomes of Surgical Therapy (COST) multicenter randomized trial tes

118 , AND PARTICIPANTS: The Clinical Outcomes of Surgical Therapy (COST) Study Group Trial assessing over

119 ample 2001-2003 [before Clinical Outcomes of Surgical Therapy (COST)] and 2005-2007 (after COST) was

120 cancers that are progressing on medical and surgical therapies designed to ablate the action of andr

121 researchers continue to explore alternative surgical therapies designed to augment cardiac function.

122 nd management of kidney disease for advanced surgical therapies (durable left ventricular assist devi

123 ibitors, and GLP-1 receptor antagonists) and surgical therapies (eg, laparoscopic surgery).

124 r MV dysfunction with either percutaneous or surgical therapy endorse the durability of MR reduction

125 transplantation remains the gold standard of surgical therapies for advanced and end-stage heart fail

126 ve roles of pharmacological and organ-saving surgical therapies for advanced heart failure, medical u

127 ssed the proliferation of minimally invasive surgical therapies for benign prostatic hyperplasia.

128 acial skeletal defects parallel the accepted surgical therapies for bone loss elsewhere in the skelet

129 survey the current non-medical, medical, and surgical therapies for childhood motor disorders.

130 d in outcomes with heart transplantation and surgical therapies for congenital heart disease along wi

131 Surgical therapies for fecal incontinence continue to ev

132 enefits of endoscopic and minimally invasive surgical therapies for GERD.

133 A variety of surgical therapies for heart failure are currently under

134 algesic drugs, vasoactive drugs, and medical/surgical therapies for intracranial hypertension.

135 standing PD and advancing the development of surgical therapies for its treatment.

136 and hospitalization when compared with other surgical therapies for men with benign prostatic hyperpl

137 2) to guide evaluation of transcatheter and surgical therapies for MR.

138 Current surgical therapies for prolapse now include augmentation

139 eview highlights the advances in the salvage surgical therapies for recurrent disease after definitiv

140 hysicians have developed and refined various surgical therapies for the treatment of Parkinson's dise

141 deal of work remains to be done, advances in surgical therapies for the treatment of Parkinson's dise

142 The present review discusses surgical therapies for the treatment of Parkinson's dise

143 Surgical therapy for 35,179 patients with stage I rectal

144 controlled trials focusing on endoscopic or surgical therapy for achalasia were included (734 total

145 cholesterol; and new concepts in medical and surgical therapy for acute intracerebral hemorrhage.

146 remains a very promising minimally invasive surgical therapy for benign prostatic hyperplasia with i

147 Complete AXLND as part of the surgical therapy for breast cancer has come under increa

148 Surgical therapy for chronic disease is not always warra

149 Surgical therapy for colorectal carcinoma metastatic to

150 has been adopted to extend the frontiers of surgical therapy for colorectal hepatic metastases.

151 ant advances in medical, interventional, and surgical therapy for coronary and peripheral arterial di

152 Surgical therapy for coronary artery disease needs to be

153 AC lung disease requires aggressive drug and surgical therapy for cure.

154 s to evaluate the regional pancreatectomy as surgical therapy for ductal adenocarcinoma of the pancre

155 for early HCC have expanded, but the use of surgical therapy for early HCC has not been examined in

156 ce of HCC is increasing, and the options for surgical therapy for early HCC have expanded, but the us

157 and analyze factors predictive of receipt of surgical therapy for early hepatocellular carcinoma (HCC

158 F is currently the most frequently performed surgical therapy for gastroesophageal reflux disease.

159 The most widely established surgical therapy for heart failure is cardiac transplant

160 s gained worldwide acceptance as the initial surgical therapy for infants with biliary atresia.

161 of different agents as a minimally invasive surgical therapy for LUTS associated with benign prostat

162 increasingly prominent role in contemporary surgical therapy for many common diseases.

163 EST-CLI trial (Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb-Threaten

164 lain the difficulty of selecting appropriate surgical therapy for patients with OSA using currently a

165 Generally, surgical therapy for Peyronie's disease can be divided i

166 rviving for 10 years after having definitive surgical therapy for primary cutaneous melanoma.

167 ues about the relative merits of medical and surgical therapy for primary hyperparathyroidism; based

168 stimulation (DBS) has emerged as a powerful surgical therapy for the management of treatment-resista

169 Effective surgical therapy for the most life-threatening manifesta

170 f parkinsonism, and the recent resurgence of surgical therapy for the treatment of hypokinetic and hy

171 It is a safe and effective alternative to surgical therapy for these tumors of 2 to 5 cm in size.

172 We review the history of surgical therapy for tuberculosis and reports of its rol

173 ngineered human arteries become mainstays of surgical therapy for vascular disease.

174 urely inflammatory phase), combined drug and surgical therapy (for the destructive phase), or surgery

175 Surgical therapies formerly contraindicated for the fail

176 Surgical therapy had significantly more CAL loss than no

177 s with advanced periodontitis who, after non-surgical therapy, had one or more sites with probing dep

178 ith chronic periodontitis who, following non-surgical therapy, had one or more sites with probing dep

179 Although surgical therapy has been shown to be an effective treat

180 Surgical therapy has varied from biopsy to radical maste

181 ction therapy, the oldest minimally invasive surgical therapy, has been investigated for over 100 yea

182 re superficial at diagnosis and, after local surgical therapy, have a high rate of local recurrence a

183 between patients who received medical versus surgical therapy (hazard ratio: 1.34; 95% confidence int

184 ty in dyads receiving advanced heart failure surgical therapies, highlighting the potential for seria

185 older heart failure patients who underwent 3 surgical therapies: HT with pretransplant MCS (HT MCS),

186 t of HCC, including expanded eligibility for surgical therapies, improved patient selection for locor

187 urpose of this review is to discuss emerging surgical therapies in heart failure, in particular, mech

188 >/= 2 years) effect of four surgical and non-surgical therapies in treating periodontal disease.

189 cluded that compared surgical therapy to non-surgical therapy in >/= 10 patients diagnosed with chron

190 Limb-sparing surgery (LSS) was the primary surgical therapy in 144 patients; 24 received amputation

191 ndmark studies will guide the application of surgical therapy in heart failure for the foreseeable fu

192 d in BEST-CLI (Best Endovascular Versus Best Surgical Therapy in Patients With Chronic Limb-Threateni

193 ST-CLI trial (Best Endovascular vs Best Open Surgical Therapy in Patients with Critical Limb Ischemia

194 nter BEST-CLI (Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia

195 alth-sponsored Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia

196 limited reports on the outcomes of intraoral surgical therapy in patients with HIV, such as crown len

197 Clinical improvements after mechanical non-surgical therapy in patients with insulin-dependent diab

198 pic therapy is emerging as an alternative to surgical therapy in patients with mucosal (T1a) esophage

199 led trials that compare medical therapy with surgical therapy in patients with type 2 diabetes are li

200 ination with AFS may improve the response of surgical therapy in reducing probing depth in severe chr

201 The role of pharmacologic and surgical therapy in remodeling is evolving and may have

202 entify manuscripts reporting response to pre-surgical therapy in renal cell carcinoma.

203 apy had significantly more CAL loss than non-surgical therapy in shallow PD.

204 d to compare the outcome of surgical and non-surgical therapy in shallow, moderate, and deep PD.

205 Current surgical therapies include ablative techniques (thalamot

206 Surgical therapy included extraction of tooth #28 and an

207 Surgical therapy included internal bevel gingivectomy co

208 y includes testosterone and GnRH analogs and surgical therapy includes mammoplasty and phalloplasty.

209 herefore, these patients can have definitive surgical therapy, including axillary dissection or maste

210 is currently a trend toward more aggressive surgical therapy, including prophylactic CLND and avoida

211 Patients received non-surgical therapy, including scaling and root planing (SR

212 ive interventions to enhance the efficacy of surgical therapy, increasing numbers of elderly people w

213 l outcomes must be used in the evaluation of surgical therapy (indeed, of all therapy) for glaucoma w

214 mulation among antiepileptic drugs and other surgical therapies is still evolving.

215 Analysis of the data further suggests that surgical therapy is a more predictable method for remova

216 Surgical therapy is currently the only proven way to ach

217 Currently, surgical therapy is largely reserved for infants failing

218 n's disease, remains unknown and medical and surgical therapy is limited.

219 Surgical therapy is not cost-effective.

220 although randomized trials demonstrate that surgical therapy is somewhat more durable and effective.

221 Surgical therapy is the main form of treatment in locali

222 Currently, surgical therapy is the most effective modality in terms

223 e highlight developments in surgical and non-surgical therapies (mainly involving the combination of

224 ases, a combination of immunosuppression and surgical therapies may be required.

225 Novel pharmacological and surgical therapies may have future implications in visua

226 ompared the impact of minimally invasive non-surgical therapy (MINST) with quadrant-wise subgingival

227 Despite surgical therapy, mortality in such patients is high.

228 detection of nonpalpable metastases altered surgical therapy (n = 2), demonstration of pharmacodynam

229 Patients receiving surgical therapy (n = 25) had a median survival of 27.8

230 Surgical therapy of atrial fibrillation concomitant to c

231 iderations and advances in the diagnosis and surgical therapy of non-union are highlighted and the ne

232 toneal (IP) chemotherapy is a promising post-surgical therapy of ovarian cancer, but the full potenti

233 of Er:YAG laser irradiation for regenerative surgical therapy of peri-implantitis-associated osseous

234 Surgical therapy of RAAs in properly selected patients p

235 Therefore, aggressive surgical therapy of regional lymph node metastases is wa

236 s clinically driven repeat interventional or surgical therapy of the index vessel at 9 month-follow-u

237 um for guidance of medical, and particularly surgical, therapy of cutaneous malignant melanoma patien

238 Surgical therapies often result in nerve and tissue dama

239 Continuous non-surgical therapy (one or more non-surgical procedures pe

240 Numerous minimally invasive surgical therapy options have arisen and subsequently fa

241 ing systemic antibiotics during initial, non-surgical therapy or in the context of periodontal surger

242 Overall outcomes for patients who underwent surgical therapy or radiation were comparable across the

243 In this study, most patients underwent surgical therapy or watchful waiting while fewer had med

244 versies in diagnosis, patient selection, and surgical therapy, our over-arching goal should be to enf

245 n concordance with guidelines for definitive surgical therapy (P < .001), postlumpectomy radiation (P

246 ided a slight benefit to the outcomes of non-surgical therapy particularly at deeper probing depths.

247 omplex biliary stone disease not amenable to surgical therapy, peroral endoscopic removal, or simple

248 Implantoplasty as an adjunct to surgical therapy proved effective in terms of disease re

249 th locoregional disease was characterized as surgical therapy, radiation therapy, chemotherapy, or an

250 nal guidelines was determined for definitive surgical therapy, radiotherapy after breast-conserving s

251 greater odds of survival included receipt of surgical therapy, recent year of treatment, increased di

252 Intermittent non-surgical therapy reduced the tooth mortality rate by 48%

253 nduced dyskinesia and motor fluctuations and surgical therapies reemerged.

254 ounding within the propensity-matched group, surgical therapy remained significantly associated with

255 Nonetheless, surgical therapy remains a cornerstone of management for

256 Whereas surgical therapy remains the most advisable therapy for

257 areas, (3) patients that receive ablative or surgical therapy require endoscopic follow-up, (4) high-

258 ogy, clinical presentation, natural history, surgical therapy, response to treatment, and prognosis h

259 Surgical therapy resulted in a significant reduction of

260 ing which patients underwent endovascular or surgical therapy (revascularization and/or amputation) a

261 he next several years, whether endoscopic or surgical therapies should be considered, and whether the

262 New medical and surgical therapies should be studied specifically in thi

263 sently there is no unanimity of opinion that surgical therapy should be offered to all patients, and

264 on 871 patients in the Clinical Outcomes of Surgical Therapy Study (NCT00002575), investigating lapa

265 There is evidence suggesting surgical therapy (surgical embolectomy or venoarterial e

266 Along with conventional surgical therapy, systemic antibiotics may provide more

267 markers and the development of effective non-surgical therapies that are fertility-sparing.

268 rical or targeted medical therapy as well as surgical therapies that lead to measurable improvement i

269 wed for the development of novel medical and surgical therapies that may potentially alter the standa

270 Uterus transplant is a surgical therapy that enables women with uterine-factor

271 e some of the problems associated with early surgical therapies, the development of new techniques an

272 Despite the striking advances in medical and surgical therapy, the morbidity, mortality, and economic

273 In the context of contemporary medical and surgical therapy, the revolutionary procedure of cardiac

274 nts with early HCC may not be candidates for surgical therapy, these data suggest that there is a sig

275 are seeing an increase in consultations for surgical therapy to help transgender and gender-nonconfo

276 Patients that underwent surgical therapy to manage peri-implantitis with a follo

277 Patients that underwent surgical therapy to manage peri-implantitis with a follo

278 e anticipated to bring a broad transition of surgical therapy to minimally invasive (minithoracotomy

279 clinical trials were included that compared surgical therapy to non-surgical therapy in >/= 10 patie

280 linical scenarios compared with conventional surgical therapy to provide clinical guidelines for the

281 hat are refractory to medical and incisional surgical therapies, transscleral diode cyclophotocoagula

282 oorly defined and the response to medical or surgical therapy unpredictable.

283 mild to moderate periodontitis received non-surgical therapy using a piezo-ceramic device (n = 30) o

284 is now in progress to evaluate survival with surgical therapy versus survival with medical therapy.

285 The rate of capturing initial surgical therapies was similar to that of identifying ca

286 Surgical therapy was associated with a very low risk of

287 Surgical therapy was completed by four periodontists (tw

288 No surgical therapy was indicated.

289 However, the stenosis worsened and surgical therapy was needed.

290 Non-surgical therapy was provided at baseline.

291 Non-surgical therapies were completed to evaluate tissue res

292 cal management, and medical, endoscopic, and surgical therapies were described in 2003, and they are

293 d trial, 45 volunteers with DH following non-surgical therapy were immediately applied with one of th

294 cal attachment level (CAL) after initial non-surgical therapy were treated with VMIS.

295 ncy, highly resistant to current medical and surgical therapies, whose tumor cells characteristically

296 lude biological neurorestorative techniques--surgical therapies with transplantation, gene therapy, a

297 Seven patients underwent surgical therapy with all CT angiographic findings confi

298 leus (STN) and globus pallidus interna, is a surgical therapy with class 1 evidence for Parkinson's d

299 Non-surgical therapy with systemic antibiotics is effective

300 e directives as antithetical to the goals of surgical therapy, yet little is known about surgeons' ap